Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Peripheral Arterial Disease (PAD) Clinical Trials

A listing of Peripheral Arterial Disease (PAD) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (10) clinical trials

A clinical trial to evaluate treatments using Beetroot juice, Beetroot juice placebo for patients

Peripheral arterial disease (PAD) is a strong predictor of cardiovascular mortality and negatively affects functional capacity and quality of life for as many as 14 million patients in the U.S. alone. One open-label study showed that acute consumption of beetroot juice improved 6 min walk performance, reduced blood pressure, and ...

Phase

Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease

Atherosclerotic peripheral artery disease (PAD) of the lower extremities afflicts up to 8% of the U.S. population and lack of adequate sustainable therapies necessarily results in severe morbidity and increased mortality. Both experimental and current clinical data indicate that GM-CSF has the capacity to mobilize a variety of progenitor cells ...

Phase

Contrast Ultrasound Perfusion Imaging in PAD With Sonazoid

The measurement of limb skeletal muscle perfusion and perfusion reserve during exercise is an approach that can assess the total impact of the complex pathophysiologic processes in patients with limb ischemia, particularly in those with diabetes in whom distal arterial disease and abnormal microvascular functional responses are common. This trial ...

Phase

The Effects of Omega-3 Fatty Acids Supplementation on Endothelial Function and Inflammation

The hypothesis being tested is that in patients with stable claudication and documented PAD, omega-3 supplementation for 1 month will lead to improvement in endothelial function as measured by flow-mediated, brachial artery vasodilation (FMD), as well as improvement in the vascular inflammatory profile as measured by a panel of established ...

Phase

SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease

To investigate the efficacy of the administration of JVS-100 delivered via direct intramuscular injections on a 3 month and 6 month composite endpoint of wound progression, healing and limb loss in patients with severe peripheral arterial disease with non-healing chronic wounds who undergo an open bypass grafting or endovascular procedure ...

Phase

Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers Endothelial Function and Safety

Primary: 1. To evaluate the effect of concomitant administration of cilostazol and probucol on the 12-week change in FMD from baseline compared, with individual drugs alone. 2. To assess the safety of concomitant administration of cilostazol and probucol in peripheral artery disease (PAD) subjects complicated with coronary artery disease (CAD) ...

Phase

Evaluation of FM220 in Patients With Peripheral Arterial Disease (PAD)

The purpose of this study is to determine whether 12 weeks of daily home use of the FM220 in the most affected leg of patients with PAD and claudication, will improve peak walking time (PWT) at three months as compared with a non-treated control group.

Phase

Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD

This is a prospective, open label, single treatment arm, multicenter phase 2 study to evaluate the safety and efficacy of the HAV in patients with PAD undergoing femoro-popliteal bypass surgery. The primary objective of this study is to evaluate the safety and tolerability of the HAV in these patients and ...

Phase

Randomized Phase IIb Trial of DVC1-0101

DVC1-0101 is a gene therapy medicine to treat peripheral arterial disease (PAD) based on recombinant F-gene-deleted, non-transmissible Sendai virus (rSeV/dF) expressing human fibroblast growth factor-2 (FGF-2) gene. The previous Phase I/IIa study demonstrated no serious adverse event related to the administration, and suggested possible improvement of local blood flow and ...

Phase

Hepatocyte Growth Factor to Improve Functioning in PAD

The HI-PAD study will randomize 39 people age 55 and older with PAD who do not have critical limb ischemia. The primary outcome is change in the six-minute walk distance at 3-month follow-up after the first study drug injection. A secondary outcome in change in six-minute walk distance at 6-month ...

Phase